Literature DB >> 17289883

Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer.

Lukas A Hefler1, Alexander Mustea, Dominique Könsgen, Nicole Concin, Berno Tanner, Reiner Strick, Georg Heinze, Christoph Grimm, Eva Schuster, Clemens Tempfer, Alexander Reinthaller, Robert Zeillinger.   

Abstract

PURPOSE: Vascular endothelial growth factor (VEGF), an important regulator of angiogenesis and vascular permeability, is involved in various steps of ovarian carcinogenesis. Gene polymorphisms within the gene encoding VEGF were shown to be independently associated with an adverse outcome in various malignancies. No data are available for ovarian cancer. EXPERIMENTAL
DESIGN: In the present multicenter study, we examined three common polymorphisms within the VEGF gene (-634G/C, -1154G/A, and -2578C/A) known to be associated with an increased VEGF production in 563 Caucasian patients with ovarian cancer from Austria and Germany using pyrosequencing. Results were correlated with clinical data.
RESULTS: The three investigated polymorphisms did not correlate with any of the investigated clinicopathologic variables. In univariate and multivariate models, no significant correlations between any polymorphism and patients' overall survival were ascertained. Simultaneous carriage of the three homozygous genotypes (i.e., VEGF -634C/C, VEGF -1154G/G, VEGF -2578C/C) known to be associated with increased VEGF expression in an individual patient, however, was independently associated with a shortened overall survival (hazard ratio, 2.1; 95% confidence interval, 1.1-3.9; P=0.02).
CONCLUSIONS: We present the first data on VEGF gene polymorphisms in ovarian cancer. Simultaneous carriage of the three investigated homozygous genotypes was shown to be an independent adverse prognosticator of overall survival.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17289883     DOI: 10.1158/1078-0432.CCR-06-1008

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  38 in total

1.  Role of five small nucleotide polymorphisms in the VEGF gene on the susceptibility to osteosarcoma and overall survival of patients.

Authors:  Jian-Qiang Liu; Xia Bai; DE-Chen Duan; Ai-Xia Dou
Journal:  Oncol Lett       Date:  2015-06-19       Impact factor: 2.967

2.  Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab.

Authors:  Vincenzo Formica; Raffaele Palmirotta; Girolamo Del Monte; Annalisa Savonarola; Giorgia Ludovici; Maria Laura De Marchis; Italia Grenga; Michele Schirru; Fiorella Guadagni; Mario Roselli
Journal:  Int J Colorectal Dis       Date:  2010-12-29       Impact factor: 2.571

3.  Effects of common germ-line genetic variation in cell cycle genes on ovarian cancer survival.

Authors:  Honglin Song; Estrid Hogdall; Susan J Ramus; Richard A Dicioccio; Claus Hogdall; Lydia Quaye; Valerie McGuire; Alice S Whittemore; Mitul Shah; David Greenberg; Douglas F Easton; Susanne Kruger Kjaer; Paul D P Pharoah; Simon A Gayther
Journal:  Clin Cancer Res       Date:  2008-02-15       Impact factor: 12.531

4.  Mismatch repair gene polymorphisms and survival in invasive ovarian cancer patients.

Authors:  Andrea Mann; Estrid Hogdall; Susan J Ramus; Richard A DiCioccio; Claus Hogdall; Lydia Quaye; Valerie McGuire; Alice S Whittemore; Mitul Shah; David Greenberg; Douglas F Easton; Bruce A J Ponder; Susanne Krüger Kjaer; Simon A Gayther; Deborah J Thompson; Paul D P Pharoah; Honglin Song
Journal:  Eur J Cancer       Date:  2008-08-22       Impact factor: 9.162

Review 5.  Intraoperative imaging in ovarian cancer: fact or fiction?

Authors:  Lucia M A Crane; Marleen van Oosten; Rick G Pleijhuis; Arash Motekallemi; Sean C Dowdy; William A Cliby; Ate G J van der Zee; Gooitzen M van Dam
Journal:  Mol Imaging       Date:  2011-04-26       Impact factor: 4.488

6.  Promoter polymorphisms of the vascular endothelial growth factor gene are associated with metabolic syndrome susceptibility in Koreans.

Authors:  Young Ree Kim; Seung-Ho Hong
Journal:  Biomed Rep       Date:  2017-04-07

Review 7.  Angiogenesis and ovarian cancer.

Authors:  César Gómez-Raposo; Marta Mendiola; Jorge Barriuso; Enrique Casado; David Hardisson; Andrés Redondo
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

8.  Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

Authors:  Bryan P Schneider; Molin Wang; Milan Radovich; George W Sledge; Sunil Badve; Ann Thor; David A Flockhart; Bradley Hancock; Nancy Davidson; Julie Gralow; Maura Dickler; Edith A Perez; Melody Cobleigh; Tamara Shenkier; Susan Edgerton; Kathy D Miller
Journal:  J Clin Oncol       Date:  2008-10-01       Impact factor: 44.544

Review 9.  Antiangiogenic drugs in ovarian cancer.

Authors:  G C Kumaran; G C Jayson; A R Clamp
Journal:  Br J Cancer       Date:  2008-11-11       Impact factor: 7.640

10.  Antivascular therapy for epithelial ovarian cancer.

Authors:  Francois P Duhoux; Jean-Pascal Machiels
Journal:  J Oncol       Date:  2009-12-23       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.